<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>KORLYM- mifepristoneÂ tabletÂ </strong><br>Corcept Therapeutics Inc<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Korlym<span class="Sup">Â®</span> safely and effectively. See full prescribing information for Korlym. <br>Korlym<span class="Sup">Â®</span> (mifepristone) 300 mg Tablets <br>Initial U.S. Approval 2000
</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING:  TERMINATION OF PREGNANCY</span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<p class="Highlighta"><span class="Bold">Mifepristone has potent antiprogestational effects and will result in the termination of pregnancy. Pregnancy must therefore be excluded before the initiation of treatment with Korlym, or if treatment is interrupted for more than 14 days in females of reproductive potential.</span> </p>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING:  TERMINATION OF PREGNANCY</span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<p class="Highlighta"><span class="Bold">Mifepristone has potent antiprogestational effects and will result in the termination of pregnancy. Pregnancy must therefore be excluded before the initiation of treatment with Korlym, or if treatment is interrupted for more than 14 days in females of reproductive potential.</span> </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Korlym (mifepristone) is a cortisol receptor blocker indicated to control <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus or <span class="product-label-link" type="condition" conceptid="44808385" conceptname="Pre-diabetes">glucose intolerance</span> and have failed surgery or are not candidates for surgery.
  (<a href="#section-1">1</a>)</p>
<p class="Highlighta"><span class="Bold">Important Limitations of Use</span>  (<a href="#section-1">1</a>)</p>
<ul class="Disc"><li>Do not use for the treatment of type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus unrelated to endogenous Cushing's syndrome.
</li></ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<ul class="Disc">
<li>Administer once daily orally with a meal (<a href="#s3">2</a>).
</li>
<li>The recommended starting dose is 300 mg once daily (<a href="#s3">2</a>).
</li>
<li><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span>:  do not exceed 600 mg once daily.
</li>
<li>Mild-to-moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>:  do not exceed 600 mg once daily.  Do not use in severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.
</li>
</ul>
<p class="Highlighta">Based on clinical response and tolerability, the dose may be increased in 300 mg increments to a maximum of 1200 mg once daily. Do not exceed 20 mg/kg per day (<a href="#s3">2</a>).
 </p>
</div>
<div><div></div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc"><li>300 mg tablet
</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li>Pregnancy (<a href="#s10">4.1</a>, <a href="#s39">8.1</a>)
</li>
<li>Use of simvastatin or lovastatin and CYP3A substrates with narrow therapeutic range (<a href="#s11">4.2</a>)
</li>
<li>Concurrent long-term corticosteroid use (<a href="#s12">4.3</a>)
</li>
<li>Women with history of unexplained <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> (<a href="#s13">4.4</a>)
</li>
<li>Women with <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span> with atypia or endometrial carcinoma (<a href="#s13">4.4</a>)
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">Adrenal insufficiency</span></span>: Patients should be closely monitored for signs and symptoms of <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span> (<a href="#s16">5.1</a>).
</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span></span>: <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> should be corrected prior to treatment and monitored for during treatment (<a href="#s17">5.2</a>).
</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal bleeding</span> and endometrial changes</span>: Women may experience endometrial thickening or unexpected <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>. Use with caution if patient also has a <span class="product-label-link" type="condition" conceptid="432869" conceptname="Hemorrhagic disorder due to circulating anticoagulants">hemorrhagic disorder</span> or is on anti-coagulant therapy (<a href="#s18">5.3</a>).
</li>
<li>
<span class="Italics">QT interval prolongation</span>: Avoid use with QT interval-prolonging drugs, or in patients with potassium channel variants resulting in a <span class="product-label-link" type="condition" conceptid="4008859" conceptname="Prolonged QT interval">long QT</span> interval (<a href="#s19">5.4</a>).
</li>
<li>
<span class="Italics">Use of Strong CYP3A Inhibitors:</span> Concomitant use can increase mifepristone plasma levels significantly. Use only when necessary and limit mifepristone dose to 300 mg (<a href="#s21">5.6</a>).
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions in Cushing's syndrome (â‰¥Â 20%): <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, decreased <span class="product-label-link" type="condition" conceptid="4107462" conceptname="k">blood potassium</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span>, endometrial <span class="product-label-link" type="condition" conceptid="4210465" conceptname="Hypertrophy">hypertrophy</span>
  (<a href="#section-6">6</a>)</p>
<p class="Highlighta"><span class="Bold">To report suspected adverse reactions, contact Corcept Therapeutics at 1-855-844-3270 or FDA at 1-800-FDA-1088 or
</span><span class="Bold Italics">www.fda.gov/medwatch.</span>  (<a href="#section-6">6</a>)</p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>Drugs metabolized by CYP3A: Administer drugs that are metabolized by CYP3A at the lowest dose when used with Korlym (<a href="#s32">7.1</a>).
</li>
<li>CYP3A inhibitors: Caution should be used when Korlym is used with strong CYP3A inhibitors.  Limit mifepristone dose to 300 mg per day when used with strong CYP3A inhibitors (<a href="#s21">5.6</a>, <a href="#s33">7.2</a>).
</li>
<li>CYP3A inducers: Do not use Korlym with CYP3A inducers (<a href="#s34">7.3</a>).
</li>
<li>Drugs metabolized by CYP2C8/2C9: Use the lowest dose of CYP2C8/2C9 substrates when used with Korlym (<a href="#s35">7.4</a>).
</li>
<li>Drugs metabolized by CYP2B6: Use of Korlym should be done with caution with bupropion and efavirenz (<a href="#s36">7.5</a>).
</li>
<li>Hormonal contraceptives: Do not use with Korlym (<a href="#s37">7.6</a>).
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc"><li>Nursing mothers: Discontinue drug or discontinue nursing (<a href="#s42">8.3</a>).
</li></ul></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
</div>
</div>
<div><div></div></div>
<div><div>
<div></div>
<div></div>
<div></div>
</div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 6/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING:  TERMINATION OF PREGNANCY
</a></h1>
<h1><a href="#section-1" class="toc">1  INDICATIONS AND USAGE
</a></h1>
<h1><a href="#section-2" class="toc">2  DOSAGE AND ADMINISTRATION
</a></h1>
<h2><a href="#section-2.1" class="toc">2.1  Adult Dosage
</a></h2>
<h2><a href="#section-2.2" class="toc">2.2  Dosing in <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</a></h2>
<h2><a href="#section-2.3" class="toc">2.3  Dosing in <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>
</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS
</a></h1>
<h1><a href="#section-4" class="toc">4  CONTRAINDICATIONS
</a></h1>
<h2><a href="#section-4.1" class="toc">4.1  Pregnancy
</a></h2>
<h2><a href="#section-4.2" class="toc">4.2  Drugs Metabolized by CYP3A
</a></h2>
<h2><a href="#section-4.3" class="toc">4.3  Corticosteroid Therapy Required for Lifesaving Purposes
</a></h2>
<h2><a href="#section-4.4" class="toc">4.4  Women with Risk of <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal Bleeding</span> or Endometrial Changes
</a></h2>
<h2><a href="#section-4.5" class="toc">4.5  Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to Mifepristone
</a></h2>
<h1><a href="#section-5" class="toc">5  WARNINGS AND PRECAUTIONS
</a></h1>
<h2><a href="#section-5.1" class="toc">5.1  <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">Adrenal Insufficiency</span>
</a></h2>
<h2><a href="#section-5.2" class="toc">5.2  <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span>
</a></h2>
<h2><a href="#section-5.3" class="toc">5.3  <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal Bleeding</span> and Endometrial Changes
</a></h2>
<h2><a href="#section-5.4" class="toc">5.4  QT Interval Prolongation
</a></h2>
<h2><a href="#section-5.5" class="toc">5.5  Exacerbation/Deterioration of Conditions Treated with Corticosteroids
</a></h2>
<h2><a href="#section-5.6" class="toc">5.6  Use of Strong CYP3A Inhibitors
</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 <span class="Italics">Pneumocystis jiroveci</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span>
</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Potential Effects of Hypercortisolemia
</a></h2>
<h1><a href="#section-6" class="toc">6  ADVERSE REACTIONS
</a></h1>
<h2><a href="#section-6.1" class="toc">6.1  Clinical Trials Experience
</a></h2>
<h2><a href="#section-6.2" class="toc">6.2  Laboratory Tests
</a></h2>
<h2><a href="#section-6.3" class="toc">6.3  <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal Bleeding</span> and Endometrial Changes
</a></h2>
<h2><a href="#section-6.4" class="toc">6.4  Additional Data from Clinical Trials
</a></h2>
<h2><a href="#section-6.5" class="toc">6.4.1  <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">Adrenal Insufficiency</span>
</a></h2>
<h2><a href="#section-6.6" class="toc">6.4.2  <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>
</a></h2>
<h1><a href="#section-7" class="toc">7  DRUG INTERACTIONS
</a></h1>
<h2><a href="#section-7.1" class="toc">7.1  Drugs Metabolized by CYP3A
</a></h2>
<h2><a href="#section-7.2" class="toc">7.2  CYP3A Inhibitors
</a></h2>
<h2><a href="#section-7.3" class="toc">7.3  CYP3A Inducers
</a></h2>
<h2><a href="#section-7.4" class="toc">7.4  Drugs Metabolized by CYP2C8/2C9
</a></h2>
<h2><a href="#section-7.5" class="toc">7.5  Drugs Metabolized by CYP2B6
</a></h2>
<h2><a href="#section-7.6" class="toc">7.6  Use of Hormonal Contraceptives
</a></h2>
<h1><a href="#section-8" class="toc">8  USE IN SPECIFIC POPULATIONS
</a></h1>
<h2><a href="#section-8.1" class="toc">8.1  Pregnancy
</a></h2>
<h2><a href="#section-8.2" class="toc">8.3  Nursing Mothers
</a></h2>
<h2><a href="#section-8.3" class="toc">8.4  Pediatric Use
</a></h2>
<h2><a href="#section-8.4" class="toc">8.5  Geriatric Use
</a></h2>
<h2><a href="#section-8.5" class="toc">8.6  <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</a></h2>
<h2><a href="#section-8.6" class="toc">8.7  <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>
</a></h2>
<h2><a href="#section-8.7" class="toc">8.8  Females of Reproductive Potential
</a></h2>
<h1><a href="#section-9" class="toc">10  OVERDOSAGE
</a></h1>
<h1><a href="#section-10" class="toc">11  DESCRIPTION
</a></h1>
<h1><a href="#section-11" class="toc">12  CLINICAL PHARMACOLOGY
</a></h1>
<h2><a href="#section-11.1" class="toc">12.1  Mechanism of Action
</a></h2>
<h2><a href="#section-11.2" class="toc">12.2  Pharmacodynamics
</a></h2>
<h2><a href="#section-11.3" class="toc">12.3  Pharmacokinetics
</a></h2>
<h1><a href="#section-12" class="toc">13  NONCLINICAL TOXICOLOGY
</a></h1>
<h2><a href="#section-12.1" class="toc">13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility
</a></h2>
<h1><a href="#section-13" class="toc">14  CLINICAL STUDIES
</a></h1>
<h2><a href="#section-13.1" class="toc">14.1  Cushing's Syndrome
</a></h2>
<h1><a href="#section-14" class="toc">16  HOW SUPPLIED/STORAGE AND HANDLING
</a></h1>
<h1><a href="#section-15" class="toc">17  PATIENT COUNSELING INFORMATION
</a></h1>
<h2><a href="#section-15.1" class="toc">17.1  Importance of Preventing Pregnancy
</a></h2>
<h2><a href="#section-15.2" class="toc">17.3  FDA-Approved Medication Guide
</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="s1"></a><a name="section-1"></a><p></p>
<h1>WARNING:  TERMINATION OF PREGNANCY
</h1>
<p class="First"><span class="Bold">Mifepristone is a potent antagonist of progesterone and cortisol via the progesterone and glucocorticoid (GR-II) receptors, respectively.  The antiprogestational effects will result in the termination of pregnancy. Pregnancy must therefore be excluded before the initiation of treatment with Korlym and prevented during treatment and for one month after stopping treatment by the use of a non-hormonal medically acceptable method of contraception unless the patient has had a surgical sterilization, in which case no additional contraception is needed. Pregnancy must also be excluded if treatment is interrupted for more than 14 days in females of reproductive potential.</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s2"></a><a name="section-1"></a><p></p>
<h1>1  INDICATIONS AND USAGE
</h1>
<p class="First">Korlym (mifepristone) is a cortisol receptor blocker indicated to control <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus or <span class="product-label-link" type="condition" conceptid="44808385" conceptname="Pre-diabetes">glucose intolerance</span> and have failed surgery or are not candidates for surgery.
</p>
<p>LIMITATIONS OF USE:
</p>
<ul class="Disc"><li>Korlym should not be used in the treatment of patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> unless it is secondary to Cushing's syndrome.
</li></ul>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s3"></a><a name="section-2"></a><p></p>
<h1>2  DOSAGE AND ADMINISTRATION
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s4"></a><a name="section-2.1"></a><p></p>
<h2>2.1  Adult Dosage
</h2>
<p class="First">The recommended starting dose is 300 mg orally once daily. Korlym must be given as a single daily dose. Korlym should always be taken with a meal. Patients should swallow the tablet whole. Do not split, crush, or chew tablets.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s5"></a><a name="section-2.1.1"></a><p></p>
<p class="First"><span class="Italics">Dosing and titration</span></p>
<p>The daily dose of Korlym may be increased in 300 mg increments. The dose of Korlym may be increased to a maximum of 1200 mg once daily but should not exceed 20Â mg/kg per day. Increases in dose should not occur more frequently than once every 2-4 weeks. Decisions about dose increases should be based on a clinical assessment of tolerability and degree of improvement in Cushing's syndrome manifestations. Changes in glucose control, anti-diabetic medication requirements, insulin levels, and <span class="product-label-link" type="condition" conceptid="4294810" conceptname="Psychiatric symptom">psychiatric symptoms</span> may provide an early assessment of response (within 6 weeks) and may help guide early dose titration. Improvements in <span class="product-label-link" type="condition" conceptid="4195232" conceptname="Cushingoid facies">cushingoid</span> appearance, <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, <span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">hirsutism</span>, <span class="product-label-link" type="condition" conceptid="137054" conceptname="Skin striae">striae</span>, and body weight occur over a longer period of time and, along with measures of glucose control, may be used to determine dose changes beyond the first 2 months of therapy. Careful and gradual titration of Korlym accompanied by monitoring for recognized adverse reactions (<span class="Italics">See Warnings and Precautions <a href="#s16">5.1</a> and <a href="#s17">5.2</a></span>) may reduce the risk of severe adverse reactions. Dose reduction or even dose discontinuation may be needed in some clinical situations. If Korlym treatment is interrupted, it should be reinitiated at the lowest dose (300Â mg). If treatment was interrupted because of adverse reactions, the titration should aim for a dose lower than the one that resulted in treatment interruption.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6"></a><a name="section-2.2"></a><p></p>
<h2>2.2  Dosing in <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</h2>
<p class="First">No change in initial dose of Korlym is required in <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. The maximum dose should be limited to 600 mg. <span class="Italics">[See <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> (<a href="#s45">8.6</a>) and Clinical Pharmacology (<a href="#s53">12.3</a>)]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7"></a><a name="section-2.3"></a><p></p>
<h2>2.3  Dosing in <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>
</h2>
<p class="First">No change in the initial dose of Korlym is required in mild to moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. The maximum dose should be limited to 600 mg. Korlym should not be used in severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. <span class="Italics">[See <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> (<a href="#s46">8.7</a>) and Clinical Pharmacology (<a href="#s53">12.3</a>)]</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s8"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS
</h1>
<p class="First">Korlym is supplied as a light yellow to yellow oval-shaped tablet debossed with â€œCorceptâ€? on one side and â€œ300â€? on the other. Each tablet contains 300 mg of mifepristone. The tablets are not scored.
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s9"></a><a name="section-4"></a><p></p>
<h1>4  CONTRAINDICATIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s10"></a><a name="section-4.1"></a><p></p>
<h2>4.1  Pregnancy
</h2>
<p class="First">Korlym is contraindicated in women who are pregnant. Pregnancy must be excluded before the initiation of treatment with Korlym or if treatment is interrupted for more than 14 days in females of reproductive potential.  Nonhormonal contraceptives should be used during and one month after stopping treatment in all women of reproductive potential. <span class="Italics">[See Use in Specific Populations <a href="#s47">8.8</a>]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s11"></a><a name="section-4.2"></a><p></p>
<h2>4.2  Drugs Metabolized by CYP3A
</h2>
<p class="First">Korlym is contraindicated in patients taking simvastatin, lovastatin, and CYP3A substrates with narrow therapeutic ranges, such as cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus, due to an increased risk of adverse events. <span class="Italics">[See Drug Interactions (<a href="#s32">7.1</a>) and Clinical Pharmacology (<a href="#s53">12.3</a>)]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12"></a><a name="section-4.3"></a><p></p>
<h2>4.3  Corticosteroid Therapy Required for Lifesaving Purposes
</h2>
<p class="First">Korlym is contraindicated in patients who require concomitant treatment with systemic corticosteroids for serious medical conditions or illnesses (e.g., <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> after organ transplantation) because Korlym antagonizes the effect of glucocorticoids.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s13"></a><a name="section-4.4"></a><p></p>
<h2>4.4  Women with Risk of <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal Bleeding</span> or Endometrial Changes
</h2>
<p class="First">Korlym is contraindicated in the following:
</p>
<ul class="Disc">
<li>Women with a history of unexplained <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>
</li>
<li>Women with <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span> with atypia or endometrial carcinoma
</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s14"></a><a name="section-4.5"></a><p></p>
<h2>4.5  Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to Mifepristone
</h2>
<p class="First">Korlym is contraindicated in patients with prior <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> to mifepristone or to any of the product components.
</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s15"></a><a name="section-5"></a><p></p>
<h1>5  WARNINGS AND PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s16"></a><a name="section-5.1"></a><p></p>
<h2>5.1  <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">Adrenal Insufficiency</span>
</h2>
<p class="First">Patients receiving mifepristone may experience <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span>. Because serum cortisol levels remain elevated and may even increase during treatment with Korlym, serum cortisol levels do not provide an accurate assessment of <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">hypoadrenalism</span> in patients receiving Korlym. Patients should be closely monitored for signs and symptoms of <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span>, including <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, increased <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. If <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span> is suspected, discontinue treatment with Korlym immediately and administer glucocorticoids without delay. High doses of supplemental glucocorticoids may be needed to overcome the glucocorticoid receptor blockade produced by mifepristone. Factors considered in deciding on the duration of glucocorticoid treatment should include the long half-life of mifepristone (85 hours).
</p>
<p>Treatment with Korlym at a lower dose can be resumed after resolution of <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span>. Patients should also be evaluated for precipitating causes of <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">hypoadrenalism</span> (<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, etc.).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s17"></a><a name="section-5.2"></a><p></p>
<h2>5.2  <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span>
</h2>
<p class="First">In a study of patients with Cushing's syndrome, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> was observed in 44% of subjects during treatment with Korlym. <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> should be corrected prior to initiating Korlym. During Korlym administration, serum potassium should be measured 1 to 2 weeks after starting or increasing the dose of Korlym and periodically thereafter. <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> can occur at any time during Korlym treatment. Mifepristone-induced <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> should be treated with intravenous or oral potassium supplementation based on event severity. If <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> persists in spite of potassium supplementation, consider adding mineralocorticoid antagonists.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s18"></a><a name="section-5.3"></a><p></p>
<h2>5.3  <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal Bleeding</span> and Endometrial Changes
</h2>
<p class="First">Being an antagonist of the progesterone receptor, mifepristone promotes unopposed endometrial proliferation that may result in endometrium thickening, cystic dilatation of endometrial glands, and <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>. Korlym should be used with caution in women who have <span class="product-label-link" type="condition" conceptid="432869" conceptname="Hemorrhagic disorder due to circulating anticoagulants">hemorrhagic disorders</span> or are receiving concurrent anticoagulant therapy. Women who experience <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> during Korlym treatment should be referred to a gynecologist for further evaluation.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s19"></a><a name="section-5.4"></a><p></p>
<h2>5.4  QT Interval Prolongation
</h2>
<p class="First">Mifepristone and its metabolites block IKr. Korlym prolongs the QTc interval in a dose-related manner. There is little or no experience with high exposure, concomitant dosing with other QT-prolonging drugs, or potassium channel variants resulting in a <span class="product-label-link" type="condition" conceptid="4008859" conceptname="Prolonged QT interval">long QT</span> interval. <span class="Italics">[See Warnings &amp; Precautions (<a href="#s21">5.6</a>)]</span> To minimize risk, the lowest effective dose should always be used.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s20"></a><a name="section-5.5"></a><p></p>
<h2>5.5  Exacerbation/Deterioration of Conditions Treated with Corticosteroids
</h2>
<p class="First">Use of Korlym in patients who receive corticosteroids for other conditions (e.g., <span class="product-label-link" type="condition" conceptid="434621" conceptname="Autoimmune disease">autoimmune disorders</span>) may lead to exacerbation or deterioration of such conditions, as Korlym antagonizes the desired effects of glucocorticoid in these clinical settings. For medical conditions in which chronic corticosteroid therapy is lifesaving (e.g., <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> in organ transplantation), Korlym is contraindicated. <span class="Italics">[See Contraindications (<a href="#s12">4.3</a>)]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s21"></a><a name="section-5.6"></a><p></p>
<h2>5.6  Use of Strong CYP3A Inhibitors
</h2>
<p class="First">Korlym should be used with extreme caution in patients taking ketoconazole and other strong inhibitors of CYP3A, such as itraconazole, nefazodone, ritonavir, nelfinavir, indinavir, atazanavir, amprenavir, fosamprenavir, boceprevir, clarithromycin, conivaptan, lopinavir, posaconazole, saquinavir, telaprevir, telithromycin, or voriconazole, as these could substantially increase the concentration of mifepristone in the blood. The benefit of concomitant use of these agents should be carefully weighed against the potential risks. Mifepristone should be used in combination with strong CYP3A inhibitors only when necessary, and in such cases the dose should be limited to 300 mg per day. <span class="Italics">[See Warnings &amp; Precautions (<a href="#s19">5.4</a>), Drug Interactions (<a href="#s33">7.2</a>), and Clinical Pharmacology (<a href="#s53">12.3</a>)]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s22"></a><a name="section-5.7"></a><p></p>
<h2>5.7 <span class="Italics">Pneumocystis jiroveci</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span>
</h2>
<p class="First">Patients with endogenous Cushing's syndrome are at risk for <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> such as <span class="Italics">Pneumocystis jiroveci</span> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> during Korlym treatment. Patients may present with <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span> shortly after initiation of Korlym. Appropriate diagnostic tests should be undertaken and treatment for <span class="Italics">Pneumocystis jiroveci</span> should be considered.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s23"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Potential Effects of Hypercortisolemia
</h2>
<p class="First">Korlym does not reduce serum cortisol levels. Elevated cortisol levels may activate mineralocorticoid receptors which are also expressed in cardiac tissues. Caution should be used in patients with underlying heart conditions including <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> and coronary vascular disease.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s24"></a><a name="section-6"></a><p></p>
<h1>6  ADVERSE REACTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s25"></a><a name="section-6.1"></a><p></p>
<h2>6.1  Clinical Trials Experience
</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed cannot be directly compared to rates in other clinical trials and may not reflect the rates observed in clinical practice.
</p>
<p>Safety data on the use of Korlym are available from 50 patients with Cushing's syndrome enrolled in an uncontrolled, open-label, multi-center trial (Study 400). Forty-three patients had Cushing's disease and all except one had previously undergone pituitary surgery. Four patients had ectopic ACTH secretion, and three had adrenal carcinoma. Patients were treated for up to 24 weeks. A dose of 300 mg per day was administered for the initial 14Â days; thereafter, the dose could be escalated in increments of 300 mg per day based on assessments of tolerability and clinical response. Doses were escalated up to 900 mg per day for patients &lt;60 kg, or 1200 mg per day for patients &gt;60 kg.
</p>
<p>The most frequently reported adverse reactions (reported in â‰¥20% of patients, regardless of relationship to Korlym) were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, decreased <span class="product-label-link" type="condition" conceptid="4107462" conceptname="k">blood potassium</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span>, and endometrial <span class="product-label-link" type="condition" conceptid="4210465" conceptname="Hypertrophy">hypertrophy</span>. Drug-related adverse events resulted in dose interruption or reduction in study drug in 40% of patients.
</p>
<p>The adverse reactions that occurred in â‰¥10% of the Cushing's syndrome patients receiving Korlym, regardless of relationship to Korlym, are shown in <a href="#t1">Table 1</a>.
</p>
<a name="t1"></a><table width="100%">
<caption><span>Table 1.  Treatment Emergent Adverse Events Occurring in â‰¥10% of Cushing's Syndrome Patients Receiving Korlym
</span></caption>
<col align="left" width="67.650%">
<col align="left" width="32.350%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Body System/Adverse Reaction</span></th>
<th class="Botrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Percent (%) of Patients Reporting Event</span><br><span class="Bold">(n = 50)</span>
</th>
</tr></thead>
<tfoot><tr class="First Last"><td align="left" colspan="2" valign="top"><p class="First Footnote">*The denominator was 26 females who had baseline and end-of-trial transvaginal ultrasound
</p></td></tr></tfoot>
<tbody>
<tr class="First"><td class="Botrule Lrule Rrule" align="left" colspan="2" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">48
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">26
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">18
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">12
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">10
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="2" valign="top"><span class="Bold">General disorders and administration/site conditions</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">48
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Edema peripheral</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">26
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">14
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="2" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">44
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">22
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">10
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="2" valign="top"><span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span></span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">30
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">16
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">14
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in extremity</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">12
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="2" valign="top"><span class="Bold">Investigations</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4107462" conceptname="k">Blood potassium</span> decreased
</td>
<td class="Botrule Rrule" align="center" valign="top">34
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4194160" conceptname="Thyroid function tests abnormal">Thyroid function test abnormal</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">18
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="2" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span></span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">14
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">12
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="2" valign="top"><span class="Bold">Metabolism and nutrition disorders</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased appetite</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">20
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">10
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="2" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span></span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">24
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="2" valign="top"><span class="Bold">Reproductive system and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">breast disorders</span></span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Endometrial <span class="product-label-link" type="condition" conceptid="4210465" conceptname="Hypertrophy">hypertrophy</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">38*
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="2" valign="top"><span class="Bold">Respiratory, thoracic, and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span></span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">16
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="2" valign="top"><span class="Bold">Psychiatric disorders</span></td></tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">10
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s26"></a><a name="section-6.2"></a><p></p>
<h2>6.2  Laboratory Tests
</h2>
<p class="First">Reductions in high density lipoprotein-<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (HDL-C) levels have been observed following treatment with Korlym. In study subjects that experienced declines in HDL-C, levels returned to baseline following discontinuation of drug. The clinical significance of the treatment-related reduction in HDL-C levels in patients with Cushing's syndrome is not known.
</p>
<p>In a study of patients with Cushing's syndrome, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> was observed in 44% of subjects during treatment with Korlym. In these cases, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> responded to treatment with potassium supplementation and/or mineralocorticoid antagonist therapy (e.g., spironolactone or eplerenone). <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> should be corrected prior to initiating Korlym. <span class="Italics">[See Warnings and Precautions (<a href="#s17">5.2</a>)]</span></p>
<p>Elevations of thyroid-stimulating hormone (TSH) were seen in subjects treated with Korlym. Of the 42Â subjects with detectable TSH at baseline, eight (19%) had increases in TSH above the normal range, while remaining asymptomatic. The TSH levels returned to normal in most patients without intervention when Korlym was discontinued at the end of the study.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s27"></a><a name="section-6.3"></a><p></p>
<h2>6.3  <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal Bleeding</span> and Endometrial Changes
</h2>
<p class="First">In Study 400, the thickness of the endometrium increased from a mean of 6.14 mm at baseline (n=23) to 15.7Â mm at end-of-trial (n=18) in premenopausal women; in postmenopausal women the increase was from 2.75Â mm (n=6) to 7.35 mm (n=8). Endometrial thickness above the upper limit of normal was reported in 10/26 females who had baseline and end-of-trial transvaginal ultrasound (38%). The endometrial thickness returned to the normal range in 3 out of 10 patients 6 weeks after treatment cessation at the end of the study. <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal bleeding</span> occurred in 5 out of 35 females (14%). Two of five subjects with <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> had normal endometrial thickness. Endometrial biopsies were performed in six patients; five of these patients had endometrial thickening. No endometrial carcinoma was detected in the sampled cases.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s28"></a><a name="section-6.4"></a><p></p>
<h2>6.4  Additional Data from Clinical Trials
</h2>
<p class="First">The following are adverse events that were reported in Study 400 at frequencies of â‰¥ 5% to 10%, and may be related to Korlym's mechanism of action:
</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>
</p>
<p><span class="Italics">General disorders and administration site conditions:</span> <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">pitting edema</span>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>
</p>
<p><span class="Italics">Investigations:</span> blood triglycerides increased
</p>
<p><span class="Italics">Metabolism and nutrition disorders:</span> <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>
</p>
<p><span class="Italics">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscular weakness</span>, <span class="product-label-link" type="condition" conceptid="4090433" conceptname="Flank pain">flank pain</span>, <span class="product-label-link" type="condition" conceptid="4092930" conceptname="Musculoskeletal chest pain">musculoskeletal chest pain</span>
</p>
<p><span class="Italics">Psychiatric disorders:</span> <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>
</p>
<p><span class="Italics">Reproductive system and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">breast disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="195012" conceptname="Intermenstrual bleeding - irregular">metrorrhagia</span> <span class="Italics">[See Warnings and Precautions (<a href="#s18">5.3</a>)]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s29"></a><a name="section-6.5"></a><p></p>
<h2>6.4.1  <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">Adrenal Insufficiency</span>
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">Adrenal insufficiency</span> was reported in two subjects (4%) in Study 400. The most typical symptoms of <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span> were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span>. No <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> or <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> was reported during the events. <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">Adrenal insufficiency</span> resolved in both cases with Korlym interruption and /or dexamethasone administration.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s30"></a><a name="section-6.6"></a><p></p>
<h2>6.4.2  <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>
</h2>
<p class="First">Generalized, maculo-<span class="product-label-link" type="condition" conceptid="141094" conceptname="Lichen">papular rash</span> was reported in 2 subjects (4%) in Study 400. Two additional subjects developed <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> (4%). None resulted in discontinuation of Korlym, and all the events resolved by the end of the study.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s31"></a><a name="section-7"></a><p></p>
<h1>7  DRUG INTERACTIONS
</h1>
<p class="First">Based on the long terminal half-life of mifepristone after reaching steady state, at least 2 weeks should elapse after cessation of Korlym before initiating or increasing the dose of any interacting concomitant medication.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s32"></a><a name="section-7.1"></a><p></p>
<h2>7.1  Drugs Metabolized by CYP3A
</h2>
<p class="First">Because Korlym is an inhibitor of CYP3A, concurrent use of Korlym with a drug whose metabolism is largely or solely mediated by CYP3A is likely to result in increased plasma concentrations of the drug. Discontinuation or dose reduction of such medications may be necessary with Korlym co-administration.
</p>
<p>Korlym increased the exposure to simvastatin and simvastatin acid significantly in healthy subjects. Concomitant use of simvastatin or lovastatin is contraindicated because of the increased risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> and <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>. <span class="Italics">[See Contraindications (<a href="#s11">4.2</a>), Clinical Pharmacology <a href="#s53">12.3</a>]</span></p>
<p>The exposure of other substrates of CYP3A with narrow therapeutic ranges, such as cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus, may be increased by concomitant administration with Korlym. Therefore, the concomitant use of such CYP3A substrates with Korlym is contraindicated. <span class="Italics">[See Contraindications (<a href="#s11">4.2</a>)]</span></p>
<p>Other drugs with similar high first pass metabolism in which CYP3A is the primary route of metabolism should be used with extreme caution if co-administered with Korlym. The lowest possible dose and/or a decreased frequency of dosing must be used with therapeutic drug monitoring when possible. Use of alternative drugs without these metabolic characteristics is advised when possible with concomitant Korlym.
</p>
<p>If drugs that undergo low first pass metabolism by CYP3A or drugs in which CYP3A is not the major metabolic route are co-administered with Korlym, use the lowest dose of concomitant medication necessary, with appropriate monitoring and follow-up. <span class="Italics">[See Clinical Pharmacology (<a href="#s53">12.3</a>)]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s33"></a><a name="section-7.2"></a><p></p>
<h2>7.2  CYP3A Inhibitors
</h2>
<p class="First">Medications that inhibit CYP3A could increase plasma mifepristone concentrations and dose reduction of Korlym may be required.
</p>
<p>Ketoconazole and other strong inhibitors of CYP3A, such as itraconazole, nefazodone, ritonavir, nelfinavir, indinavir, atazanavir, amprenavir and fosamprenavir, boceprevir, clarithromycin, conivaptan, lopinavir, mibefradil, , posaconazole, , saquinavir, telaprevir, telithromycin, or voriconazole may increase exposure to mifepristone significantly. The clinical impact of this interaction has not been studied. Therefore, extreme caution should be used when these drugs are prescribed in combination with Korlym. The benefit of concomitant use of these agents should be carefully weighed against the potential risks. The dose of Korlym should be limited to 300 mg and used only when necessary. <span class="Italics">[See Warnings &amp; Precautions (<a href="#s21">5.6</a>)]</span></p>
<p>Moderate inhibitors of CYP3A, such as amprenavir, aprepitant, atazanavir, ciprofloxacin, darunavir/ritonavir, diltiazem, erythromycin, fluconazole, fosamprenavir, grapefruit juice, imatinib, or verapamil, should be used with caution when administered in combination with Korlym.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s34"></a><a name="section-7.3"></a><p></p>
<h2>7.3  CYP3A Inducers
</h2>
<p class="First">No medications that induce CYP3A have been studied when co-administered with Korlym. Avoid co-administration of Korlym and CYP3A inducers such as rifampin, rifabutin, rifapentin, phenobarbital, phenytoin, carbamazepine, and St. John's wort.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s35"></a><a name="section-7.4"></a><p></p>
<h2>7.4  Drugs Metabolized by CYP2C8/2C9
</h2>
<p class="First">Because Korlym is an inhibitor of CYP2C8/2C9, concurrent use of Korlym with a drug whose metabolism is largely or solely mediated by CYP2C8/2C9 is likely to result in increased plasma concentrations of the drug.
</p>
<p>Korlym significantly increased exposure of fluvastatin, a typical CYP2C8/2C9 substrate, in healthy subjects. When given concomitantly with Korlym, drugs that are substrates of CYP2C8/2C9 (including non-steroidal anti-inflammatory drugs, warfarin, and repaglinide) should be used at the smallest recommended doses, and patients should be closely monitored for adverse effects. <span class="Italics">[See Clinical Pharmacology (<a href="#s53">12.3</a>)]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s36"></a><a name="section-7.5"></a><p></p>
<h2>7.5  Drugs Metabolized by CYP2B6
</h2>
<p class="First">Mifepristone is an inhibitor of CYP2B6 and may cause significant increases in exposure of drugs that are metabolized by CYP2B6 such as bupropion and efavirenz. Since no study has been conducted to evaluate the effect of mifepristone on substrates of CYP2B6, the concomitant use of bupropion and efavirenz should be undertaken with caution. <span class="Italics">[See Clinical Pharmacology (<a href="#s53">12.3</a>)]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s37"></a><a name="section-7.6"></a><p></p>
<h2>7.6  Use of Hormonal Contraceptives
</h2>
<p class="First">Mifepristone is a progesterone-receptor antagonist and will interfere with the effectiveness of hormonal contraceptives. Therefore, non-hormonal contraceptive methods should be used.
</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s38"></a><a name="section-8"></a><p></p>
<h1>8  USE IN SPECIFIC POPULATIONS
</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="s39"></a><a name="section-8.1"></a><p></p>
<h2>8.1  Pregnancy
</h2>
<p class="First">Category X
</p>
<p>Korlym is contraindicated in pregnancy. Korlym can cause fetal harm when administered to a pregnant woman because the use of Korlym results in pregnancy loss. The inhibition of both endogenous and exogenous progesterone by mifepristone at the progesterone receptor results in pregnancy loss. If Korlym is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus. <span class="Italics">[See Contraindications (<a href="#s10">4.1</a>)]</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="s40"></a><a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Italics">Human Data</span></p>
<p>In a report of thirteen live births after single dose mifepristone exposure, no fetal abnormalities were noted.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s41"></a><a name="section-8.1.2"></a><p></p>
<p class="First"><span class="Italics">Animal Data</span></p>
<p>Teratology studies in mice, rats and rabbits at doses of 0.25 to 4.0 mg/kg (less than human exposure at the maximum clinical dose, based on body surface area) were carried out. Because of the anti-progestational activity of mifepristone, fetal losses were much higher than in control animals. Skull deformities were detected in rabbit studies at less than human exposure, although no teratogenic effects of mifepristone have been observed to date in rats or mice. These deformities were most likely due to the mechanical effects of uterine contractions resulting from antagonism of the progesterone receptor.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s42"></a><a name="section-8.2"></a><p></p>
<h2>8.3  Nursing Mothers
</h2>
<p class="First">Mifepristone is present in human milk of women taking the drug. Because of the potential for serious adverse reactions in nursing infants from Korlym, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s43"></a><a name="section-8.3"></a><p></p>
<h2>8.4  Pediatric Use
</h2>
<p class="First">Safety and effectiveness of Korlym in pediatric patients have not been established.
</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s44"></a><a name="section-8.4"></a><p></p>
<h2>8.5  Geriatric Use
</h2>
<p class="First">Clinical studies with Korlym did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently than younger people.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s45"></a><a name="section-8.5"></a><p></p>
<h2>8.6  <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</h2>
<p class="First">The maximum dose should not exceed 600 mg per day in renally impaired patients. <span class="Italics">[See Clinical Pharmacology (<a href="#s53">12.3</a>)]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s46"></a><a name="section-8.6"></a><p></p>
<h2>8.7  <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>
</h2>
<p class="First">In patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, the maximum dose should not exceed 600 mg per day.  The pharmacokinetics of mifepristone in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> has not been studied, and Korlym should not be used in these patients<span class="Italics">. [See Clinical Pharmacology (<a href="#s53">12.3</a>)]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s47"></a><a name="section-8.7"></a><p></p>
<h2>8.8  Females of Reproductive Potential
</h2>
<p class="First">Due to its anti-progestational activity, Korlym causes pregnancy loss. Exclude pregnancy before the initiation of treatment with Korlym or if treatment is interrupted for more than 14 days in females of reproductive potential. Recommend contraception for the duration of treatment and for one month after stopping treatment using a non-hormonal medically acceptable method of contraception. If the patient has had surgical sterilization, no additional contraception is needed.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s48"></a><a name="section-9"></a><p></p>
<h1>10  OVERDOSAGE
</h1>
<p class="First">There is no experience with overdosage of Korlym.
</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s49"></a><a name="section-10"></a><p></p>
<h1>11  DESCRIPTION
</h1>
<p class="First">Korlym (mifepristone) is a cortisol receptor blocker for oral administration. The chemical name of mifepristone is 11Î²-(4-dimethylaminophenyl)-17Î²-hydroxy-17Î±-(1-propynyl)-estra-4, 9-dien-3-one. The chemical formula is C<span class="Sub">29</span>H<span class="Sub">35</span>NO<span class="Sub">2</span>; the molecular weight is 429.60, and the structural formula is:
</p>
<div class="Figure">
<a name="f01"></a><img alt="Figure
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=542f3fae-8bc8-4f00-9228-e4b66c9ad6a9&amp;name=kor00-0000-01.jpg">
</div>
<p>Mifepristone demonstrates a pH-related solubility profile. The greatest solubility is achieved in acidic media (~ 25 mg/mL at pH 1.5) and solubility declines rapidly as the pH is increased. At pH values above 2.5 the solubility of mifepristone is less than 1 mg/mL.
</p>
<p>Each Korlym tablet for oral use contains 300 mg of mifepristone. The inactive ingredients of Korlym tablets are silicified microcrystalline cellulose, sodium starch glycolate, hydroxypropylcellulose, sodium lauryl sulfate, magnesium stearate, hypromellose, titanium dioxide, triacetin, D&amp;C yellow 10 aluminum lake, polysorbate 80, and FD&amp;C yellow 6 aluminum lake.
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s50"></a><a name="section-11"></a><p></p>
<h1>12  CLINICAL PHARMACOLOGY
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="s51"></a><a name="section-11.1"></a><p></p>
<h2>12.1  Mechanism of Action
</h2>
<p class="First">Mifepristone is a selective antagonist of the progesterone receptor at low doses and blocks the glucocorticoid receptor (GR-II) at higher doses. Mifepristone has high affinity for the GR-II receptor but little affinity for the GR-I (MR, mineralocorticoid) receptor. In addition, mifepristone appears to have little or no affinity for estrogen, muscarinic, histaminic, or monoamine receptors.
</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="s52"></a><a name="section-11.2"></a><p></p>
<h2>12.2  Pharmacodynamics
</h2>
<p class="First">Because mifepristone acts at the receptor level to block the effects of cortisol, its antagonistic actions affect the hypothalamic-pituitary-adrenal (HPA) axis in such a way as to further increase circulating cortisol levels while, at the same time, blocking their effects.
</p>
<p>Mifepristone and the three active metabolites have greater affinity for the glucocorticoid receptor (100%, 61%, 48%, and 45%, respectively) than either dexamethasone (23%) or cortisol (9%).
</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s53"></a><a name="section-11.3"></a><p></p>
<h2>12.3  Pharmacokinetics
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s54"></a><a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Italics">Absorption</span></p>
<p>Following oral administration, time to peak plasma concentrations of mifepristone occurred between 1 and 2 hours following single dose, and between 1 and 4 hours following multiple doses of 600 mg of Korlym in healthy volunteers. Mean plasma concentrations of three active metabolites of mifepristone peak between 2 and 8 hours after multiple doses of 600 mg/day, and the combined concentrations of the metabolites exceed that of the parent mifepristone. Exposure to mifepristone is substantially less than dose proportional. Time to steady state is within 2 weeks, and the mean (SD) half-life of the parent mifepristone was 85 (61) hours following multiple doses of 600 mg/day of Korlym.
</p>
<p>Studies evaluating the effects of food on the pharmacokinetics of Korlym demonstrate a significant increase in plasma levels of mifepristone when dosed with food. To achieve consistent plasma drug concentrations, patients should be instructed to always take their medication with meals.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s55"></a><a name="section-11.3.2"></a><p></p>
<p class="First"><span class="Italics">Distribution</span></p>
<p>Mifepristone is highly bound to alpha-1-acid glycoprotein (AAG) and approaches saturation at doses of 100 mg (2.5 Î¼M) or more. Mifepristone and its metabolites also bind to albumin and are distributed to other tissues, including the central nervous system (CNS). As determined in vitro by equilibrium dialysis, binding of mifepristone and its three active metabolites to human plasma proteins was concentration-dependent. Binding was approximately 99.2% for mifepristone, and ranged from 96.1 to 98.9% for the three active metabolites at clinically relevant concentrations.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s56"></a><a name="section-11.3.3"></a><p></p>
<p class="First"><span class="Italics">Metabolism</span></p>
<p>Cytochrome P450 3A4 (CYP3A4) has been shown to be involved in mifepristone metabolism in human liver microsomes. Two of the known active metabolites are the product of demethylation (one monodemethylated and one di-demethylated), while a third active metabolite results from hydroxylation (monohydroxylated).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s57"></a><a name="section-11.3.4"></a><p></p>
<p class="First"><span class="Italics">Elimination and Excretion</span></p>
<p>Excretion is primarily (approximately 90%) via the fecal route.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s58"></a><a name="section-11.3.5"></a><p></p>
<p class="First"><span class="Bold">Specific Populations</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="s59"></a><a name="section-11.3.5.1"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p>The pharmacokinetics of mifepristone in subjects with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance [CrCL] &lt; 30 mL/min, but not on dialysis) was evaluated following multiple doses of 1200 mg Korlym for 7 days. Mean exposure to mifepristone increased 31%, with similar or smaller increases in metabolite exposure as compared to subjects with normal renal function (CrCL â‰¥ 90 mL/min). There was large variability in the exposure of mifepristone and its metabolites in subjects with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> as compared to subjects with normal renal function (geometric least square mean ratio [CI] for AUC of mifepristone: 1.21 [0.71-2.06]; metabolite 1: 1.43 [0.84-2.44]; metabolite 2: 1.18 [0.64-2.17] and metabolite 3: 1.19 [0.71-1.99]). No change in the initial dose of Korlym is needed for <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>; the maximum dose should not exceed 600 mg per day.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s60"></a><a name="section-11.3.5.2"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></p>
<p>The pharmacokinetics of mifepristone in subjects with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Class B) was evaluated in a single- and multiple-dose study (600 mg for 7 days). The pharmacokinetics in subjects with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> was similar to those with normal hepatic function. There was large variability in the exposure of mifepristone and its metabolites in subjects with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> as compared to subjects with normal hepatic function (geometric least square mean ratio [CI] for AUC of mifepristone: 1.02 [0.59-1.76]; metabolite 1: 0.95 [0.52-1.71]; metabolite 2: 1.37 [0.71-2.62] and metabolite 3: 0.62 [0.33-1.16]).  Due to limited information on safety in patients with mild-to-moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, the maximum dose should not exceed 600 mg per day. The pharmacokinetics of mifepristone in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> has not been studied. Korlym is not recommended in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s61"></a><a name="section-11.3.6"></a><p></p>
<p class="First"><span class="Bold">Drug-Drug Interactions</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="s62"></a><a name="section-11.3.6.1"></a><p></p>
<p class="First"><span class="Italics">In Vitro Assessment of Drug Interactions</span></p>
<p>In vitro studies indicate a potential for CYP-mediated drug interactions by mifepristone and/or its metabolites with substrates of CYP2A6, CYP2C8/2C9, CYP2C19, CYP3A4, CYP1A2, CYP2B6, CYP2D6, and CYP2E1. In vitro studies also indicated an interaction potential for drug transport mediated by P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). In vitro studies indicate mifepristone metabolism is mediated by CYP3A, and that mifepristone also inhibits and induces CYP3A.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e62"></a><a name="section-11.3.6.2"></a><p></p>
<p class="First"><span class="Italics">In Vivo Assessment of Drug Interactions (see <a href="#t2">Table 2</a>)</span></p>
<a name="t2"></a><table width="100%">
<caption><span>Table 2.  Summary Table of Korlym Drug-Drug Interaction Effects
</span></caption>
<col align="left" width="26.317%">
<col align="left" width="18.167%">
<col align="left" width="20.200%">
<col align="left" width="19.783%">
<col align="left" width="7.533%">
<col align="left" width="8.000%">
<tfoot>
<tr class="First"><td align="left" colspan="6" valign="top"><p class="First Footnote">*No effect = 90% CI within range 0.80 â€“ 1.25
</p></td></tr>
<tr><td align="left" colspan="6" valign="top"><p class="First Footnote"><span class="Sup">1</span> Simvastatin 40 mg dose used as reference for the comparison.  Result could be representative of other oral drugs with CYP3A metabolism and high first pass effect: cyclosporine, midazolam, triazolam, pimozide, sildenafil, sirolimus, and tacrolimus
</p></td></tr>
<tr><td align="left" colspan="6" valign="top"><p class="First Footnote"><span class="Sup">2</span> Result could be representative of other oral drugs with CYP3A metabolism and low first pass effect. Clinical significance of any interaction will depend on the therapeutic margin of the drug.
</p></td></tr>
<tr><td align="left" colspan="6" valign="top"><p class="First Footnote"><span class="Sup">3</span> Result could be representative of other oral drugs with CYP2C8/C9 metabolism
</p></td></tr>
<tr><td align="left" colspan="6" valign="top"><p class="First Footnote"><span class="Sup">4</span> Plasma digoxin concentration should be measured after 1 to 2 weeks of concomitant use and following usual clinical practice at appropriate intervals thereafter.
</p></td></tr>
<tr class="Last"><td align="left" colspan="6" valign="top"><p class="First Footnote"><span class="Sup">5</span>Result could be representative of other mild inhibitors of CYP3A
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="middle"><span class="Bold">Dosing of<br>Mifepristone</span></td>
<td class="Botrule Rrule Toprule" align="center" rowspan="2" valign="middle"><span class="Bold">Coadministered<br>Drug</span></td>
<td class="Botrule Rrule Toprule" align="center" rowspan="2" valign="middle"><span class="Bold">Dosing of<br>Coadministered<br>Drug</span></td>
<td class="Botrule Rrule Toprule" align="center" colspan="3" valign="middle"><span class="Bold">Geometric Mean Ratio<br>(analyte ratio with/without<br>drug coadministration)<br></span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Analyte</span></td>
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">AUC</span></td>
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">Cmax</span></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="6" valign="top"><span class="Bold">Effect of Korlym on Coadministered Drug</span></td></tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="6" valign="top">
<span class="Bold">Contraindicated with mifepristone
</span><span class="Italics">[See Contraindications (<a href="#s9">4</a>)]</span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">1200 mg once daily for 10 days
</td>
<td class="Botrule Rrule" align="center" valign="middle">simvastatin<span class="Sup">1</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">80 mg single dose
</td>
<td class="Botrule Rrule" align="center" valign="middle">simvastatin<br>acid<br>simvastatin
</td>
<td class="Botrule Rrule" align="center" valign="middle">15.70<br><br>10.40
</td>
<td class="Botrule Rrule" align="center" valign="middle">18.20<br><br>7.02
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="6" valign="top">
<span class="Bold">Use lowest dose of coadministered drug,</span> based on clinical  experience and/or use of therapeutic drug monitoring
</td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">1200 mg once daily for 10 days
</td>
<td class="Botrule Rrule" align="center" valign="middle">alprazolam<span class="Sup">2</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">1 mg single dose
</td>
<td class="Botrule Rrule" align="center" valign="middle">alprazolam<br>4-hydroxy-alprazolam
</td>
<td class="Botrule Rrule" align="center" valign="middle">1.80<br><br>0.76
</td>
<td class="Botrule Rrule" align="center" valign="middle">0.81<br><br>0.39
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">1200 mg once daily for 7 days
</td>
<td class="Botrule Rrule" align="center" valign="middle">fluvastatin<span class="Sup">3</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">40 mg single dose
</td>
<td class="Botrule Rrule" align="center" valign="middle">fluvastatin
</td>
<td class="Botrule Rrule" align="center" valign="middle">3.57
</td>
<td class="Botrule Rrule" align="center" valign="middle">1.76
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">1200 mg once daily for 10 days
</td>
<td class="Botrule Rrule" align="center" valign="middle">digoxin<span class="Sup">4</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">0.125 mg once daily
</td>
<td class="Botrule Rrule" align="center" valign="middle">digoxin
</td>
<td class="Botrule Rrule" align="center" valign="middle">1.40
</td>
<td class="Botrule Rrule" align="center" valign="middle">1.64
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="6" valign="middle"><span class="Bold">Effect of Coadministered Drug on Korlym</span></td></tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="6" valign="middle"><span class="Bold">No dosing adjustment required</span></td></tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="middle">300 mg once daily for 14 days
</td>
<td class="Botrule Rrule" align="center" valign="middle">cimetidine<span class="Sup">5</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">800 mg once daily
</td>
<td class="Botrule Rrule" align="center" valign="middle">mifepristone
</td>
<td class="Botrule Rrule" align="center" valign="middle">0.85*
</td>
<td class="Botrule Rrule" align="center" valign="middle">0.75
</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="s63"></a><a name="section-12"></a><p></p>
<h1>13  NONCLINICAL TOXICOLOGY
</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="s64"></a><a name="section-12.1"></a><p></p>
<h2>13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<p class="First">Mifepristone was evaluated for carcinogenicity potential in rats and mice. Rats were dosed for up to two years at doses of 5, 25, and 125 mg/kg of mifepristone. The high dose was the maximum tolerated dose, but exposure at all doses was below exposure at the maximum clinical dose based on AUC comparison. Female rats had a statistically significant increase in follicular cell <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span>/carcinomas and liver <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span>. It is plausible that these tumors are due to drug-induced enzyme metabolism, a mechanism not considered clinically relevant, but studies confirming this mechanism were not conducted with mifepristone. Mice were also tested for up to 2 years at mifepristone doses up to the maximum tolerated dose of 125 mg/kg, which provided exposure below the maximum clinical dose based on AUC. No drug-related tumors were seen in mice.
</p>
<p>Mifepristone was not genotoxic in a battery of bacterial, yeast, and mammalian in vitro assays, and an in vivo micronucleus study in mice.
</p>
<p>The pharmacological activity of mifepristone disrupts the estrus cycle of adult rats at a dose of 0.3 mg/kg (less than human exposure at the maximum clinical dose, based on body surface area). However, following withdrawal of treatment and subsequent resumption of the estrus cycle, there was no effect on reproductive function when mated.
</p>
<p>A single subcutaneous dose of mifepristone (up to 100 mg/kg) to rats on the first day after birth did not adversely affect future reproductive function in males or females, although the onset of puberty was slightly premature in dosed females. Repeated doses of mifepristone (1 mg every other day) to neonatal rats resulted in potentially adverse fertility effects, including oviduct and ovary malformations in females, delayed male puberty, deficient male sexual behavior, reduced testicular size, and lowered ejaculation frequency.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s65"></a><a name="section-13"></a><p></p>
<h1>14  CLINICAL STUDIES
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s66"></a><a name="section-13.1"></a><p></p>
<h2>14.1  Cushing's Syndrome
</h2>
<p class="First">An uncontrolled, open-label, 24-week, multicenter clinical study was conducted to evaluate the safety and efficacy of Korlym in the treatment of endogenous Cushing's syndrome. The study enrolled 50 subjects with clinical and biochemical evidence of hypercortisolemia despite prior surgical treatment and radiotherapy. The reasons for medical treatment were failed surgery, recurrence of disease, and poor medical candidate for surgery. Forty-three patients (86%) had Cushing's disease, four patients (8%) had ectopic ACTH secretion, and three (6%) had adrenal carcinoma. Baseline characteristics included: mean age of 45 years (range 26 to 71), mean BMI of 36 kg/m<span class="Sup">2</span> (range 24 to 66), mean weight 100 kg (range 61 to 199), and mean waist circumference was 119 cm (range 89 to 178); 70% were female; 84% were white and 16% were black or African American. Baseline mean urinary free cortisol level was 365Â Î¼g per 24 hr.
</p>
<p>Patients belonged to one of two cohorts: a â€œdiabetesâ€? cohort (29 patients, 26 with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> and 3 with <span class="product-label-link" type="condition" conceptid="44808385" conceptname="Pre-diabetes">glucose intolerance</span>), and a â€œhypertensionâ€? cohort (21 patients). Efficacy was evaluated separately in the two cohorts. Korlym treatment was started in all patients at a dose of 300 mg once a day. The study protocol allowed an increase in dose to 600 mg after 2 weeks, and then by additional 300Â mg increments every 4 weeks to a maximum of 900 mg per day for patients &lt;60 kg, or 1200 mg per day for patients &gt;60Â kg, based on clinical tolerance and clinical response.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s67"></a><a name="section-13.1.1"></a><p></p>
<p class="First"><span class="Italics">Results in the <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> cohort</span></p>
<p>Patients in the <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> cohort underwent standard oral glucose tolerance tests at baseline and periodically during the clinical study. Anti-diabetic medications were allowed but had to be kept stable during the trial and patients had to be on stable anti-diabetic regimens prior to enrollment. The primary efficacy analysis for the <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> cohort was an analysis of responders. A responder was defined as a patient who had a â‰¥Â 25% reduction from baseline in glucose AUC. The primary efficacy analysis was conducted in the modified intent-to-treat population (n=25) defined as all patients who received a minimum of 30 days on Korlym. Fifteen of 25 patients (60%) were treatment responders (95% CI: 39%,78%).
</p>
<p>Mean HbA1c was 7.4% in the 24 patients with HbA1c values at baseline and Week 24. For these 24 patients mean reduction in HbA1c was 1.1% (95% CI -1.6, -0.7) from baseline to the end of the trial. Fourteen of 24 patients had above normal HbA1c levels at baseline, ranging between 6.7% and 10.4%; all of these patients had reductions in HbA1c by the end of the study (range -0.4 to -4.4%) and eight of 14 patients (57%) normalized HbA1c levels at trial end. Antidiabetic medications were reduced in 7 of the 15 DM subjects taking antidiabetic medication and remained constant in the others.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s68"></a><a name="section-13.1.2"></a><p></p>
<p class="First"><span class="Italics">Results in the <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> cohort</span></p>
<p>There were no changes in mean systolic and diastolic blood pressures at the end of the trial relative to baseline in the modified intent-to-treat population (n=21).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s69"></a><a name="section-13.1.3"></a><p></p>
<p class="First"><span class="Italics">Signs and symptoms of Cushing's syndrome in both cohorts</span></p>
<p>Individual patients showed varying degrees of improvement in Cushing's syndrome manifestations such as <span class="product-label-link" type="condition" conceptid="4195232" conceptname="Cushingoid facies">cushingoid</span> appearance, <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, <span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">hirsutism</span>, <span class="product-label-link" type="condition" conceptid="137054" conceptname="Skin striae">striae</span>, <span class="product-label-link" type="condition" conceptid="4294810" conceptname="Psychiatric symptom">psychiatric symptoms</span>, and excess total body weight. Because of the variability in clinical presentation and variability of response in this open label trial, it is uncertain whether these changes could be ascribed to the effects of Korlym.
</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s70"></a><a name="section-14"></a><p></p>
<h1>16  HOW SUPPLIED/STORAGE AND HANDLING
</h1>
<p class="First">Korlym is supplied as a light yellow to yellow, film-coated, oval-shaped tablet debossed with â€œCorceptâ€? on one side and â€œ300â€? on the other. Each tablet contains 300 mg of mifepristone. Korlym tablets are available in bottles of 28 tablets (NDC 76346-073-01) and bottles of 280 tablets (NDC 76346-073-02).
</p>
<p>Store at controlled room temperature, 25 Â°C (77 Â°F); excursions permitted to 15 to 30 Â° C (59 â€“ 86 Â°F). <span class="Italics">[See USP Controlled Room Temperature]</span></p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s71"></a><a name="section-15"></a><p></p>
<h1>17  PATIENT COUNSELING INFORMATION
</h1>
<p class="First">As a part of patient counseling, doctors must review the Korlym Medication Guide with every patient. <span class="Italics">[See FDA-Approved Medication Guide (<a href="#s73">17.3</a>)]</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="s72"></a><a name="section-15.1"></a><p></p>
<h2>17.1  Importance of Preventing Pregnancy
</h2>
<ul class="Disc">
<li>Advise patients that Korlym will cause termination of pregnancy.  Korlym is contraindicated in pregnant patients.
</li>
<li>Counsel females of reproductive potential regarding pregnancy prevention and planning with a non-hormonal contraceptive prior to use of Korlym and up to one month after the end of treatment.
</li>
<li>Instruct patients to contact their physician immediately if they suspect or confirm they are pregnant.
</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s73"></a><a name="section-15.2"></a><p></p>
<h2>17.3  FDA-Approved Medication Guide
</h2>
<p class="First"></p>
</div>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="s74"></a><a name="section-16"></a><p></p>
<p class="First"><span class="Bold">Medication Guide<br>Korlym</span><span class="Bold"><span class="Sup">Â®
</span></span><span class="Bold">(KOR-lim)<br>(mifepristone) tablets</span></p>
<p>Read this Medication Guide before you start taking Korlym and each time you get a refill. There may be new information.  This information does not take the place of talking with your doctor about your medical condition or treatment.
</p>
<p><a name="p01"></a><span class="Bold">What is the most important information I should know about Korlym?</span></p>
<p><span class="Bold">Korlym can cause serious side effects, including:</span></p>
<ul class="Disc"><li>
<span class="Bold">Loss of a pregnancy.</span>  Women who can become pregnant must:<ul class="Square">
<li>have a <span class="product-label-link" type="condition" conceptid="4094448" conceptname="Pregnancy test negative">negative pregnancy test</span> before starting Korlym
</li>
<li>have a <span class="product-label-link" type="condition" conceptid="4094448" conceptname="Pregnancy test negative">negative pregnancy test</span> before restarting Korlym if you stop taking it for more than 14 days
</li>
<li>use a non-hormonal form of birth control while taking Korlym and for 1Â month after stopping Korlym.  Talk to your doctor about how to prevent pregnancy.  Tell your doctor right away if you think you may be pregnant.
</li>
</ul>
</li></ul>
<p><span class="Bold">What is Korlym?</span></p>
<p>Korlym is a prescription medicine used to treat high blood sugar (<span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>) caused by high cortisol levels in the blood (hypercortisolism) in adults with endogenous Cushing's syndrome who have type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus or <span class="product-label-link" type="condition" conceptid="44808385" conceptname="Pre-diabetes">glucose intolerance</span> and have failed surgery or cannot have surgery.
</p>
<p>Korlym is not for people who have type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus not caused by Cushing's syndrome.
</p>
<p>It is not known if Korlym is safe and effective in children.
</p>
<p><span class="Bold">Who should not take Korlym?</span></p>
<p><span class="Bold">Do not take Korlym if you:</span></p>
<ul class="Disc">
<li>
<span class="Bold">are pregnant.</span>  See â€œ<a href="#p01">What is the most important information I should know about Korlym?</a>â€?
</li>
<li>
<span class="Bold">are taking:</span><ul class="Circle">
<li>simvastatin (Zocor<span class="Sup">Â®</span>, Vytorin<span class="Sup">Â®</span>, Juvisync<span class="Sup">Â®</span>, Simcor<span class="Sup">Â®</span>)
</li>
<li>lovastatin (Mevacor<span class="Sup">Â®</span>, Altoprev<span class="Sup">Â®</span>, Advicor<span class="Sup">Â®</span>)
</li>
<li>cyclosporine (Gengraf<span class="Sup">Â®</span>, Neoral<span class="Sup">Â®</span>, Restasis<span class="Sup">Â®</span>, Sandimmune<span class="Sup">Â®</span>)
</li>
<li>dihydroergotamine (Migranal<span class="Sup">Â®</span>)
</li>
<li>ergotamine (Ergomar<span class="Sup">Â®</span>, Migergot<span class="Sup">Â®</span>)
</li>
<li>fentanyl (Abstral<span class="Sup">Â®</span>, Actiq<span class="Sup">Â®</span>, Duragesic<span class="Sup">Â®</span>, Fentora<span class="Sup">Â®</span>, Lazanda<span class="Sup">Â®</span>, Onsolis<span class="Sup">Â®</span>, Sublimaze Preservative Free<span class="Sup">Â®</span>, Subsys<span class="Sup">Â®</span>)
</li>
<li>pimozide (Orap<span class="Sup">Â®</span>)
</li>
<li>quinidine (Neudexta<span class="Sup">Â®</span>)
</li>
<li>sirolimus (Rapamune<span class="Sup">Â®</span>, Torisel<span class="Sup">Â®</span>)
</li>
<li>tacrolimus (Prograf<span class="Sup">Â®</span>, Protopic<span class="Sup">Â®</span>)
</li>
</ul>
</li>
<li>must take corticosteroid medicines for other serious medical problems
</li>
<li>are a woman who still has her uterus (womb) <span class="Bold">and</span> have:<ul class="Circle">
<li>unexplained <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> from your vagina
</li>
<li>changes in the cells lining your uterus (<span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span>) or cancer of the lining of your uterus (endometrial cancer)
</li>
</ul>
</li>
<li>are allergic to mifepristone or any of the ingredients in Korlym.  See the end of this Medication Guide for a complete list of ingredients in Korlym.
</li>
</ul>
<p>Talk to your doctor before taking Korlym if you have any of these conditions.
</p>
<p><span class="Bold">What should I tell my doctor before taking Korlym?</span></p>
<p>Before taking Korlym, tell your doctor if you:
</p>
<ul class="Square">
<li>have low potassium in your blood (<span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>)
</li>
<li>have or have had a <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> problem or are taking medicines to thin your blood
</li>
<li>have or have had heart problems
</li>
<li>have had an organ transplant
</li>
<li>have been taking medicines called corticosteroids (cortisone, dexamethasone, methylprednisolone, prednisolone, prednisone)
</li>
<li>are breastfeeding or plan to breastfeed.  Korlym passes into your breast milk and may harm your baby.  You and your doctor should decide if you will take Korlym or breastfeed.  You should not do both.
</li>
</ul>
<p><span class="Bold">Tell your doctor about all of the medicines you take,</span> including prescription and nonprescription medicines, vitamins and herbal supplements.
</p>
<p>Using Korlym with certain other medicines can affect each other.  Using Korlym with other medicines can cause serious side effects.
</p>
<p>Especially tell your doctor if you take:
</p>
<ul class="Square">
<li>medicines to treat:<ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> (such as ketoconazole)
</li>
<li><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> C <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>
</li>
<li>certain <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>
</li>
</ul>
</li>
<li>steroid medicines such as prednisone
</li>
<li>thyroid hormones
</li>
</ul>
<p>Ask your doctor or pharmacist for a list of these medicines if you are not sure.
</p>
<p>Know the medicines you take. Keep a list of them to show to your doctor and pharmacist.
</p>
<p><span class="Bold">How should I take Korlym?</span></p>
<ul class="Square">
<li>Take Korlym exactly as your doctor tells you.
</li>
<li>Your doctor may change your dose if needed.
</li>
<li>Korlym is usually taken 1 time each day.
</li>
<li>Take Korlym with food.
</li>
<li>Swallow Korlym whole.  <span class="Bold">Do not</span> split, crush or chew Korlym tablets.  If you cannot swallow Korlym tablets whole, tell your doctor.
</li>
</ul>
<p><span class="Bold">What should I avoid while taking Korlym?</span></p>
<p>You should not drink grapefruit juice while you take Korlym.  Grapefruit juice may increase the amount of Korlym in your blood and increase your chance of having side effects.
</p>
<p><span class="Bold">What are the possible side effects of Korlym?</span></p>
<p><span class="Bold">Korlym can cause serious side effects including:</span></p>
<ul class="Disc">
<li><span class="Bold">See â€œ<a href="#p01">What is the most important information I should know about Korlym?</a>â€?</span></li>
<li>
<span class="Bold">reduced effects of adrenal hormones (<span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span>)</span>. Korlym stops an adrenal hormone in your body called cortisol from working.  Tell your doctor right away if you have any symptoms of <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span>.  Symptoms may include:<ul class="Circle">
<li>unusual <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">low blood pressure</span> (<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>)
</li>
<li>low blood sugar (<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>)
</li>
</ul>
</li>
<li>
<span class="Bold">low <span class="product-label-link" type="condition" conceptid="4107462" conceptname="k">blood potassium</span> (<span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>)</span>.  Your doctor should check the level of potassium in your blood before you start taking Korlym and while you take it.  Tell your doctor if you have any signs of low potassium.  Signs may include:<ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">aches</span>, or <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span>
</li>
<li>abnormal or irregular heartbeats (<span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>)
</li>
</ul>
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> from the vagina.</span>  Korlym may cause the lining of your uterus to become thick and may cause your uterus to bleed.  Tell your doctor right away about any <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> from your vagina that is not normal for you.
</li>
<li><span class="Bold">problems with the electrical system of your heart (QT interval prolongation).</span></li>
<li><span class="Bold">worsening of symptoms of other medical problems that are treated with corticosteroids when you take corticosteroids and Korlym at the same time.</span></li>
</ul>
<p>The most common side effects of Korlym include:
</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>
</li>
<li>low potassium in your blood
</li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in your arms and legs (<span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>)
</li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your arms and legs (<span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>)
</li>
<li>high blood pressure
</li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span>
</li>
<li>thickening of the lining of the uterus (endometrial <span class="product-label-link" type="condition" conceptid="4210465" conceptname="Hypertrophy">hypertrophy</span>)
</li>
</ul>
<p>Tell your doctor if you have any side effect that bothers you or that does not go away.
</p>
<p>These are not all the possible side effects of Korlym.  For more information, ask your doctor or pharmacist.
</p>
<p>Call your doctor for medical advice about side effects.  You may report side effects to FDA at 1-800-FDA-1088.
</p>
<p><span class="Bold">How should I store Korlym?</span></p>
<p>Store Korlym at room temperature, between 68Â°F to 77Â°F (20Â°C to 25Â°C).
</p>
<p><span class="Bold">Keep Korlym and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about the safe and effective use of Korlym</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide.
</p>
<p>Do not use Korlym for a condition for which it was not prescribed.  Do not give Korlym to other people, even if they have the same symptoms you have.  It may harm them.
</p>
<p>This Medication Guide summarizes the most important information about Korlym.  If you would like more information, talk with your doctor.  You can ask your doctor or pharmacist for information about Korlym that is written for healthcare professionals.
</p>
<p>For more information, call 1-855-4Korlym (1-855-456-7596) or visit www.korlym.com or www.corcept.com.
</p>
<p><span class="Bold">What are the ingredients in Korlym?</span></p>
<p><span class="Bold">Active ingredient</span>: mifepristone
</p>
<p><span class="Bold">Inactive ingredients</span>: silicified microcrystalline cellulose, sodium starch glycolate, hydroxypropylcellulose, sodium lauryl sulfate, magnesium stearate, hypromellose, titanium dioxide, triacetin, D&amp;C yellow 10 aluminum lake, polysorbate 80, and FD&amp;C yellow 6 aluminum lake.
</p>
<p>This Medication Guide has been approved by the US Food and Drug Administration.
</p>
<p>Manufactured for:<br>Corcept Therapeutics Incorporated<br>Menlo Park, CA 94025
</p>
<p>Korlym<span class="Bold"><span class="Sup">Â®</span></span>  is a registered trademark of Corcept Therapeutics Incorporated.
</p>
<p>Â©2013 Corcept Therapeutics Incorporated. All rights reserved.
</p>
<p>K-00004 JUN 2013
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s75"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold Underline">PRINCIPAL DISPLAY PANEL  - for 28 Tablets Bottle Label</span></p>
<p>NDC 76346-073-01
</p>
<p>28 Tablets     <span class="Bold">Rx only</span></p>
<p><span class="Bold">Korlym
</span><span class="Sup">Â®</span></p>
<p>mifepristone
</p>
<ul class="Disc"><li><span class="Bold">300 mg Tablets</span></li></ul>
<p><span class="Bold">Take tablets whole. Do not split, crush or chew.</span></p>
<p><span class="Bold">ATTENTION PHARMACIST</span>: Dispense attached Medication Guide to each patient.
</p>
<p>================================================================
</p>
<div class="Figure">
<a name="f02"></a><img alt="PRINCIPAL DISPLAY PANEL  - for 28 Tablets Bottle Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=542f3fae-8bc8-4f00-9228-e4b66c9ad6a9&amp;name=kor00-0000-02.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s76"></a><a name="section-18"></a><p></p>
<p class="First"><span class="Bold Underline">PRINCIPAL DISPLAY PANEL  - for 280 Tablets Bottle Label</span></p>
<p>NDC 76346-073-02
</p>
<p>280 Tablets      <span class="Bold">Rx only</span></p>
<p><span class="Bold">Korlymâ„¢</span></p>
<p>mifepristone
</p>
<ul class="Disc"><li><span class="Bold">300 mg Tablets</span></li></ul>
<p><span class="Bold">Take tablets whole. Do not split, crush or chew.</span></p>
<p><span class="Bold">ATTENTION PHARMACIST</span>:  Dispense attached Medication Guide to each patient
</p>
<div class="Figure">
<a name="f03"></a><img alt="PRINCIPAL DISPLAY PANEL  - for 280 Tablets Bottle Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=542f3fae-8bc8-4f00-9228-e4b66c9ad6a9&amp;name=kor00-0000-03.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>KORLYMÂ 		
					</strong><br><span class="contentTableReg">mifepristone tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:76346-073</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MIFEPRISTONE</strong> (MIFEPRISTONE) </td>
<td class="formItem">MIFEPRISTONE</td>
<td class="formItem">300Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRIACETIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ALUMINUM OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">yellow (yellow) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (OVAL) </td>
<td class="formLabel">Size</td>
<td class="formItem">16mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">CORCEPT;300
</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:76346-073-01</td>
<td class="formItem">28  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:76346-073-02</td>
<td class="formItem">280  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA202107</td>
<td class="formItem">02/17/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Corcept Therapeutics Inc
							(069540610)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 6/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>3c23b920-420b-4b0e-bb55-74586a0e007f</div>
<div>Set id: 542f3fae-8bc8-4f00-9228-e4b66c9ad6a9</div>
<div>Version: 5</div>
<div>Effective Time: 20150618</div>
</div>
</div>Â <div class="DistributorName">Corcept Therapeutics Inc</div></p>
</body></html>
